By Aaron Tallent
Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) was effective in suppressing HIV viral load, even among adults who had adherence challenges, according findings that were presented at IDWeek 2023, held in Boston (abstracts 1561 and 1611).
The two nucleoside reverse transcriptase inhibitors (NRTIs) FTC and TAF work together to block reverse transcriptase, which turns viral RNA into DNA, while BIC inhibits that DNA from integrating with human DNA.